MetaVia Inc. (NASDAQ:MTVA) Sees Significant Growth in Short Interest

MetaVia Inc. (NASDAQ:MTVA) was the target of a large growth in short interest during the month of January. As of January 15th, there was short interest totaling 163,195 shares, a growth of 729.1% from the December 31st total of 19,683 shares. Approximately 7.5% of the shares of the stock are sold short. Based on an average trading volume of 234,028 shares, the short-interest ratio is presently 0.7 days. Based on an average trading volume of 234,028 shares, the short-interest ratio is presently 0.7 days. Approximately 7.5% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on MTVA. Wall Street Zen raised shares of MetaVia from a “sell” rating to a “hold” rating in a research note on Saturday, January 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MetaVia in a research report on Monday, December 22nd. Finally, HC Wainwright upped their price target on MetaVia from $12.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $36.50.

Hedge Funds Weigh In On MetaVia

A hedge fund recently bought a new stake in MetaVia stock. Virtu Financial LLC bought a new stake in MetaVia Inc. (NASDAQ:MTVA) in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm bought 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned 0.14% of MetaVia at the end of the most recent reporting period. Institutional investors and hedge funds own 1.37% of the company’s stock.

MetaVia Stock Performance

Shares of MTVA stock traded up $0.02 during mid-day trading on Thursday, hitting $2.36. The company’s stock had a trading volume of 96,434 shares, compared to its average volume of 278,796. The company has a market cap of $5.19 million, a PE ratio of -0.28 and a beta of 0.27. The company’s fifty day simple moving average is $7.32 and its 200-day simple moving average is $8.43. MetaVia has a 52 week low of $2.33 and a 52 week high of $23.10.

MetaVia (NASDAQ:MTVA) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($1.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.86) by $1.32. On average, equities analysts anticipate that MetaVia will post -3.9 earnings per share for the current year.

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.